Chapter 33 — Anti-Cancer Drugs Part I — Module 2 — Alkylating Agents
1. A patient in a hematology unit is receiving prophylactic voriconazole during a cyclophosphamide-containing conditioning regimen. Integrating the drug's activation pathway with the azole's enzyme effect, what is the most likely consequence of this combination?
A) Increased acrolein generation and a higher risk of hemorrhagic cystitis from accelerated prodrug turnover
B) Increased formation of phosphoramide mustard and greater antitumor effect from enzyme induction
C) Reduced conversion of cyclophosphamide to its active metabolite, potentially compromising antitumor efficacy
D) No pharmacokinetic interaction, because cyclophosphamide is activated by spontaneous hydrolysis rather than enzymes
E) Reduced renal clearance of active metabolites, raising systemic exposure and overall toxicity
ANSWER: C
Rationale:
Option C is correct. Cyclophosphamide is a prodrug whose activation depends on cytochrome P450 enzymes, principally CYP2B6 with a contribution from CYP3A4. Azole antifungals such as voriconazole are potent CYP3A4 inhibitors, so co-administration reduces conversion of cyclophosphamide to its active alkylating metabolite, potentially compromising antitumor effect. This interaction is clinically relevant precisely because hematology patients frequently receive prophylactic azoles during conditioning.
Option A: Option A is incorrect because azole-mediated CYP inhibition reduces, rather than accelerates, prodrug activation, so acrolein generation would tend to fall, not rise.
Option B: Option B is incorrect because azoles inhibit rather than induce CYP3A4; active metabolite formation decreases.
Option D: Option D is incorrect because cyclophosphamide requires enzymatic CYP activation, not spontaneous hydrolysis (the latter describes temozolomide), so a real interaction exists.
Option E: Option E is incorrect because the dominant interaction is reduced hepatic activation, not impaired renal clearance of metabolites.
2. A trainee asks why mesna is mandatory with ifosfamide at every dose but is generally reserved for high-dose cyclophosphamide. Integrating acrolein pharmacokinetics with the two drugs' metabolism, what is the best explanation?
A) Ifosfamide generates a greater acrolein load per gram of drug, so urothelial protection is required at all ifosfamide doses
B) Mesna is required for ifosfamide because it crosses the blood-brain barrier and prevents encephalopathy, unlike with cyclophosphamide
C) Ifosfamide produces phosphoramide mustard in the bladder lumen, which mesna neutralizes only at high cyclophosphamide doses
D) Cyclophosphamide does not generate acrolein at all, so mesna is never strictly necessary for it
E) Mesna is mandatory for ifosfamide because ifosfamide is renally cleared while cyclophosphamide is hepatically cleared
ANSWER: A
Rationale:
Option A is correct. Both drugs generate acrolein, which is excreted in urine and injures the urothelium, but ifosfamide produces a higher acrolein load per gram of drug. Because the urotoxic burden is greater at any ifosfamide dose, mesna is mandatory whenever ifosfamide is used, whereas forced hydration alone often suffices for standard-dose cyclophosphamide and mesna is reserved for high-dose regimens.
Option B: Option B is incorrect because mesna acts in the urinary tract to bind acrolein; it does not prevent ifosfamide encephalopathy, which is caused by chloroacetaldehyde and treated with methylene blue.
Option C: Option C is incorrect because the urotoxin reaching the bladder is acrolein, not phosphoramide mustard, and mesna binds acrolein.
Option D: Option D is incorrect because cyclophosphamide does generate acrolein; mesna is simply not always required at standard doses because the load is lower.
Option E: Option E is incorrect because both drugs are eliminated with renal involvement, and the deciding factor is the per-gram acrolein load, not a clearance-route difference.
3. A patient with low muscle mass has a serum creatinine that overestimates true renal function, leading to an overestimated GFR (glomerular filtration rate) entered into the Calvert formula for carboplatin. Integrating carboplatin's elimination with AUC-based dosing, what is the predicted consequence?
A) Carboplatin exposure will be lower than intended, risking underdosing and reduced antitumor effect
B) Carboplatin exposure will be higher than intended, increasing the risk of dose-limiting thrombocytopenia
C) Carboplatin nephrotoxicity will rise sharply because the drug is metabolized to a tubular toxin
D) There will be no change in exposure, because carboplatin dosing is independent of renal function
E) Carboplatin will accumulate in the central nervous system, producing neurotoxicity rather than myelosuppression
ANSWER: B
Rationale:
Option B is correct. Carboplatin is eliminated almost entirely by renal filtration as the intact complex, so GFR is the primary determinant of exposure, and the Calvert formula sets the dose as target AUC multiplied by (GFR plus 25). If GFR is overestimated, the formula assigns a higher dose than appropriate, producing greater-than-intended exposure and a heightened risk of the dose-limiting toxicity, thrombocytopenia.
Option A: Option A is incorrect because an overestimated GFR yields a higher calculated dose and higher exposure, not underdosing.
Option C: Option C is incorrect because carboplatin is relatively non-nephrotoxic and is not converted to a tubular toxin; the consequence of overexposure is myelosuppression.
Option D: Option D is incorrect because carboplatin dosing is strongly dependent on renal function through the Calvert formula.
Option E: Option E is incorrect because carboplatin overexposure causes thrombocytopenia, not CNS (central nervous system) accumulation and neurotoxicity.
4. A microsatellite-unstable (mismatch-repair-deficient) colorectal tumor has proven resistant to a cisplatin-based regimen, yet an oxaliplatin-based regimen is proposed. Integrating adduct recognition with cross-resistance principles, what is the rationale?
A) Oxaliplatin forms interstrand cross-links while cisplatin forms none, so only oxaliplatin damages this tumor's DNA
B) Oxaliplatin is not cross-resistant with cisplatin because it is eliminated by a different route, escaping the resistance mechanism
C) Oxaliplatin uptake uses a transporter absent in cisplatin handling, so the tumor cannot exclude it
D) Oxaliplatin's bulky DACH adducts evade mismatch-repair recognition, so it retains activity where mismatch-repair-dependent cisplatin sensitivity is lost
E) Oxaliplatin reverses mismatch-repair deficiency, restoring the apoptotic response that cisplatin requires
ANSWER: D
Rationale:
Option D is correct. Cisplatin-induced apoptosis depends in part on mismatch repair (MMR) proteins recognizing platinum adducts. Oxaliplatin carries a diaminocyclohexane (DACH) carrier ligand, producing bulkier adducts that are not recognized by MMR proteins. In an MMR-deficient tumor, the MMR-dependent component of cisplatin sensitivity is lost, but oxaliplatin's MMR-independent cytotoxicity is preserved, so cross-resistance with cisplatin is only partial.
Option A: Option A is incorrect because cisplatin can form interstrand cross-links; the distinguishing feature is oxaliplatin's MMR-evading bulky adduct, not an inability of cisplatin to cross-link.
Option B: Option B is incorrect because the basis for retained activity is adduct recognition, not a difference in elimination route.
Option C: Option C is incorrect because the explanation is evasion of MMR recognition of the adduct, not a unique uptake transporter.
Option E: Option E is incorrect because oxaliplatin does not restore MMR function; it acts through MMR-independent cytotoxicity.
5. A patient scheduled for ifosfamide has hypoalbuminemia, an elevated serum creatinine, and a history of prior cisplatin therapy. Integrating these features with ifosfamide's metabolism, what do they collectively predict?
A) A reduced risk of any ifosfamide toxicity, because renal impairment slows formation of the active metabolite
B) An increased risk of hemorrhagic cystitis specifically, unrelated to the listed factors
C) An increased risk of ifosfamide encephalopathy, for which these are recognized risk factors
D) A reduced acrolein load, because hypoalbuminemia increases free-drug clearance
E) An increased risk of pulmonary fibrosis, because prior cisplatin sensitizes the lung
ANSWER: C
Rationale:
Option C is correct. Ifosfamide encephalopathy, driven by the neurotoxic metabolite chloroacetaldehyde, is more likely in the presence of recognized risk factors that include hypoalbuminemia, renal impairment with elevated creatinine, and prior cisplatin exposure. The combination of all three should heighten vigilance for confusion, somnolence, and ataxia during and after the infusion.
Option A: Option A is incorrect because these factors increase, rather than decrease, the risk of encephalopathy.
Option B: Option B is incorrect because the listed factors specifically predict encephalopathy risk; hemorrhagic cystitis risk relates chiefly to acrolein load and mesna use.
Option D: Option D is incorrect because hypoalbuminemia is a risk factor for encephalopathy, not a mechanism that lowers acrolein burden.
Option E: Option E is incorrect because pulmonary fibrosis is a cumulative carmustine toxicity, not an ifosfamide risk predicted by these factors.
6. A platinum-resistant tumor demonstrates both high ERCC1 (excision repair cross-complementation group 1) expression and elevated glutathione S-transferase activity. Integrating these two findings, how do they jointly account for resistance?
A) They act through distinct steps — adduct repair and drug inactivation — so resistance is reinforced by two independent mechanisms
B) They are the same mechanism described two ways, since ERCC1 is the enzyme that conjugates glutathione to platinum
C) They cancel each other out, so the tumor should in fact be platinum-sensitive despite the laboratory values
D) They both reduce cellular platinum uptake by downregulating the copper transporter CTR1
E) They both act by reversing O6-guanine alkylation, the dominant lesion produced by platinum agents
ANSWER: A
Rationale:
Option A is correct. ERCC1 is an incision endonuclease of nucleotide excision repair that removes platinum-DNA adducts, while glutathione and glutathione S-transferase inactivate the electrophilic platinum species before it can bind DNA and export the conjugates. These operate at different points — one repairing damage, the other preventing it — so high levels of both reinforce resistance through independent, convergent mechanisms.
Option B: Option B is incorrect because ERCC1 is a repair endonuclease, not a glutathione-conjugating enzyme; the two are distinct.
Option C: Option C is incorrect because both findings independently promote resistance; they do not offset each other.
Option D: Option D is incorrect because neither ERCC1 nor glutathione S-transferase acts by downregulating CTR1; reduced uptake via CTR1 is a separate mechanism.
Option E: Option E is incorrect because reversal of O6-guanine alkylation is the MGMT mechanism relevant to methylating agents, not to platinum adducts handled by NER and glutathione.
7. A covering clinician unfamiliar with nitrosoureas prescribes lomustine on a standard 4-week cycle, as is common for many other regimens. Applying nitrosourea myelosuppression kinetics, what is the most likely outcome?
A) Improved tumor control, because more frequent dosing increases cumulative DNA cross-linking
B) No adverse effect, because lomustine myelosuppression resolves fully within two weeks like most agents
C) Acute hemorrhagic cystitis, because shorter intervals raise urinary acrolein concentrations
D) Reduced efficacy, because a 4-week interval gives insufficient time for adduct formation between doses
E) Severe cumulative myelosuppression, because the second dose lands before the delayed 4-to-6-week nadir of the first
ANSWER: E
Rationale:
Option E is correct. Nitrosoureas produce a characteristically delayed myelosuppressive nadir at 4 to 6 weeks, with recovery requiring 6 to 8 weeks, which is why cycles are spaced no more often than every 6 weeks. Administering a second dose at 4 weeks delivers it before the first dose's nadir has occurred, producing overlapping, cumulative myelosuppression that can be severe.
Option A: Option A is incorrect because more frequent dosing does not improve control; it produces dangerous marrow toxicity.
Option B: Option B is incorrect because nitrosourea myelosuppression is delayed and prolonged, not resolved within two weeks.
Option C: Option C is incorrect because hemorrhagic cystitis relates to acrolein from cyclophosphamide and ifosfamide, not to lomustine scheduling.
Option D: Option D is incorrect because the hazard of short intervals is cumulative myelosuppression, not reduced efficacy from inadequate adduct formation.
8. An elderly patient with newly diagnosed glioblastoma has an unmethylated MGMT (O6-methylguanine-DNA methyltransferase) promoter. Integrating the biomarker with treatment selection, which statement is most accurate?
A) The unmethylated status predicts strong temozolomide benefit, so temozolomide alone is clearly preferred
B) The unmethylated status predicts reduced temozolomide benefit, because intact MGMT efficiently repairs O6-guanine lesions
C) The unmethylated status is irrelevant to temozolomide and informs only the choice between nitrosoureas
D) The unmethylated status predicts increased temozolomide toxicity but unchanged efficacy
E) The unmethylated status mandates intrathecal temozolomide to overcome the repair enzyme
ANSWER: B
Rationale:
Option B is correct. An unmethylated MGMT promoter means the repair enzyme is expressed and efficiently reverses temozolomide-induced O6-methylguanine lesions, so the benefit from temozolomide is substantially reduced. In the elderly, this status helps steer therapy: methylated patients derive more benefit from temozolomide, whereas unmethylated patients gain comparatively less and may be directed toward radiation-based approaches.
Option A: Option A is incorrect because unmethylated status predicts less, not more, temozolomide benefit.
Option C: Option C is incorrect because MGMT methylation is the strongest predictor of temozolomide benefit; it is highly relevant to temozolomide, and it does not bind nitrosourea response in the same binary way.
Option D: Option D is incorrect because the dominant effect of intact MGMT is reduced efficacy through lesion repair, not selectively increased toxicity.
Option E: Option E is incorrect because temozolomide is given orally and penetrates the central nervous system well; intrathecal administration is not used and does not overcome MGMT repair.
9. A patient on rifampin for a mycobacterial infection is started on cyclophosphamide. Integrating rifampin's enzyme effect with cyclophosphamide's activation and clearance, which description best captures the interaction?
A) Rifampin induces CYP enzymes, accelerating prodrug activation (raising active metabolite and toxicity) while also speeding prodrug clearance (potentially lowering exposure and efficacy)
B) Rifampin inhibits CYP enzymes, uniformly reducing both toxicity and efficacy of cyclophosphamide
C) Rifampin has no interaction with cyclophosphamide, which is activated by spontaneous hydrolysis
D) Rifampin blocks renal excretion of active metabolites, increasing toxicity without affecting activation
E) Rifampin chelates acrolein in the urinary tract, reducing the risk of hemorrhagic cystitis
ANSWER: A
Rationale:
Option A is correct. Rifampin is a potent inducer of CYP enzymes, including CYP2B6 and CYP3A4. Induction accelerates the activation of cyclophosphamide to its active alkylating metabolite (and to acrolein), which can increase toxicity, while the same induction can deplete the parent prodrug more rapidly, reducing overall exposure and potentially compromising efficacy. The net clinical effect reflects these opposing pressures.
Option B: Option B is incorrect because rifampin induces rather than inhibits CYP enzymes.
Option C: Option C is incorrect because cyclophosphamide requires CYP activation, so a real interaction exists; spontaneous hydrolysis describes temozolomide.
Option D: Option D is incorrect because the dominant interaction is enzyme induction altering activation and clearance, not a block of renal excretion.
Option E: Option E is incorrect because urinary acrolein binding is the role of mesna, not rifampin.
10. A young man with a curable testicular germ cell tumor is to receive BEP (bleomycin, etoposide, platinum). A clinician suggests substituting carboplatin for cisplatin to spare the patient nephrotoxicity and ototoxicity. Integrating efficacy and toxicity considerations, what is the best response?
A) Substitute carboplatin freely, since the two platinums form identical adducts and are therefore interchangeable in all settings
B) Substitute carboplatin, because in curative-intent regimens lower toxicity always outweighs any efficacy difference
C) Do not substitute, because the superior cure data in this curative setting are specific to cisplatin and carboplatin underperforms here
D) Substitute oxaliplatin instead, which is the standard platinum for germ cell tumors
E) Avoid platinum entirely, since carboplatin and cisplatin are completely cross-resistant in untreated disease
ANSWER: C
Rationale:
Option C is correct. Although carboplatin shares the platinum-DNA adduct mechanism and a gentler toxicity profile, the curative outcome data in testicular germ cell tumors are specific to cisplatin, and carboplatin underperforms in this curative-intent setting. Carboplatin should not be substituted for cisplatin in BEP, where preserving cure probability outweighs the toxicity advantage.
Option A: Option A is incorrect because identical adduct chemistry does not make the two interchangeable in curative regimens where outcome data are cisplatin-specific.
Option B: Option B is incorrect because in a curable disease the priority is maintaining cure probability, so lower toxicity does not automatically justify substitution.
Option D: Option D is incorrect because oxaliplatin is used in colorectal and selected gastrointestinal cancers, not germ cell tumors.
Option E: Option E is incorrect because cross-resistance is a feature of previously treated disease and does not apply to first-line curative therapy; platinum is essential here.
11. A cell line carries a loss-of-function mutation in the Fanconi anemia repair pathway. Integrating cross-link biology with DNA repair, how should this line respond to a bifunctional alkylating agent that forms interstrand cross-links?
A) It should be resistant, because Fanconi anemia pathway loss prevents the drug from forming cross-links
B) It should be unaffected, because interstrand cross-links are repaired solely by mismatch repair, which is intact
C) It should be resistant, because loss of the pathway upregulates glutathione-mediated drug inactivation
D) It should be hypersensitive, because the Fanconi anemia pathway is required to resolve interstrand cross-links
E) It should respond normally, because interstrand cross-links are not lethal and require no repair pathway
ANSWER: D
Rationale:
Option D is correct. The Fanconi anemia (FA) pathway, working with the ERCC1-XPF nuclease, is essential for resolving interstrand cross-links (ICLs). When the FA pathway is lost, cells cannot repair ICLs produced by bifunctional alkylating agents (platinum, nitrogen mustards, mitomycin C) and become markedly hypersensitive to these drugs, paralleling the clinical hypersensitivity seen in patients with Fanconi anemia.
Option A: Option A is incorrect because loss of a repair pathway does not prevent cross-link formation; the drug still forms ICLs, and they go unrepaired.
Option B: Option B is incorrect because interstrand cross-links are resolved by the FA pathway in conjunction with nucleotide excision repair, not by mismatch repair alone.
Option C: Option C is incorrect because FA pathway loss does not upregulate glutathione detoxification; the dominant consequence is failed cross-link repair and hypersensitivity.
Option E: Option E is incorrect because interstrand cross-links are among the most lethal lesions and absolutely require repair; without it, cells die.
12. During busulfan conditioning, a patient is also receiving an azole antifungal that inhibits CYP3A4 (cytochrome P450 3A4). Integrating busulfan metabolism with its principal serious toxicity, what is the central concern, and how is it mitigated?
A) The azole induces busulfan metabolism, lowering exposure and risking graft failure, mitigated by increasing the dose empirically
B) CYP3A4 inhibition can raise busulfan exposure, increasing the risk of sinusoidal obstruction syndrome, mitigated by therapeutic drug monitoring of busulfan AUC
C) The interaction increases acrolein production, raising hemorrhagic cystitis risk, mitigated by mesna
D) The azole accelerates renal busulfan clearance, lowering efficacy, mitigated by adding hydration
E) There is no metabolic concern, because busulfan is eliminated unchanged by the kidney independent of CYP
ANSWER: B
Rationale:
Option B is correct. Busulfan is metabolized in part by hepatic CYP3A4 (and glutathione conjugation), so a CYP3A4 inhibitor can raise busulfan exposure. Because the most serious non-hematologic toxicity of high-dose busulfan is hepatic sinusoidal obstruction syndrome (SOS), and SOS risk rises with over-exposure, therapeutic drug monitoring of busulfan AUC is used to keep exposure within target and reduce that risk.
Option A: Option A is incorrect because the azole inhibits rather than induces CYP3A4, so exposure rises, and empiric dose increase would worsen the risk.
Option C: Option C is incorrect because acrolein and hemorrhagic cystitis belong to cyclophosphamide and ifosfamide, not busulfan.
Option D: Option D is incorrect because the interaction involves hepatic CYP3A4 metabolism, not accelerated renal clearance.
Option E: Option E is incorrect because busulfan undergoes hepatic metabolism (CYP3A4 and glutathione conjugation) and is not eliminated unchanged by the kidney independent of CYP.
13. A patient on procarbazine for lymphoma is also taking a selective serotonin reuptake inhibitor (SSRI) for depression and reports a diet that includes aged cheeses and red wine. Integrating procarbazine's metabolic property with these exposures, what should be anticipated?
A) A disulfiram-like reaction limited to the cheese, with no risk from the SSRI
B) Reduced procarbazine efficacy, because the SSRI accelerates its hepatic clearance
C) Hemorrhagic cystitis, because procarbazine generates acrolein like the nitrogen mustards
D) No interaction, because procarbazine has no effect on monoamine metabolism
E) Risk of serotonin syndrome from the SSRI and hypertensive crisis from tyramine-rich foods, because procarbazine is a weak monoamine oxidase inhibitor
ANSWER: E
Rationale:
Option E is correct. Procarbazine is metabolized by monoamine oxidase and is itself a weak monoamine oxidase inhibitor (MAOI). Combining it with a serotonergic agent such as an SSRI risks serotonin syndrome, and consuming tyramine-rich foods (aged cheeses, red wine, fermented meats) risks hypertensive crisis. These interactions follow directly from its MAOI property and warrant counseling.
Option A: Option A is incorrect because the SSRI poses a real serotonin syndrome risk; the danger is not limited to a disulfiram-like reaction with food.
Option B: Option B is incorrect because the principal concern is MAO inhibition causing dangerous interactions, not accelerated clearance reducing efficacy.
Option C: Option C is incorrect because procarbazine alkylates DNA but is not associated with acrolein-mediated hemorrhagic cystitis, which is a cyclophosphamide and ifosfamide toxicity.
Option D: Option D is incorrect because procarbazine does affect monoamine metabolism as a weak MAO inhibitor, so meaningful interactions exist.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.